Recently, DOACs have been tested for the treatment and secondary prevention of VTE in patients with cancer head‐to‐head against LMWHs according to the CLOT regimen (dalteparin 200 IU/kg for 1 month, followed by dalteparin 150 IE/kg) in 4 studies, which provide evidence for the efficacy and safety of DOACs, in particular factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban).12, 13, 14, 15. Here, F10 is linked to cancer.